PALISADE BIO INC (PALI)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$1.33-1.48%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge PALISADE BIO INC’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	433,012
EPS	—	-0.066
Annual ending 2026-12-31
Revenue	—	500,000
EPS	—	-0.224
Annual ending 2027-12-31
Revenue	—	47.71M
EPS	—	-0.282

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Strengthen Board and governance with new director appointments	New board members strengthen governance.	Intact	failure to enhance board governance by end of 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Newly stated in 2026-Q2. Management announced appointments of two new directors to the Board to enhance governance and expertise. This is a recent development with no prior quarters stating this priority, indicating initial delivery on governance strengthening. Delivery assessment Oct 24, 2026
Maintain disciplined operating expense management	Management is focused on controlling operating expenses despite no revenue.	Intact	operating loss exceeds $11 million per quarter persistently	Operating income: $-11.698M FY2026-Q2; GAAP. Published target: operating loss not exceeding $11 million per quarter. Target period is not explicitly aligned with this observation. Source published Aug 10, 2026-11,698,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: fa7cb221-ea63-4e34-aaae-d45006ffdc7a. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Advance Phase 2 study enrollment for PALI-2108 in Ulcerative Colitis	Palisade Bio is advancing its Phase 2 trial for PALI-2108 in ulcerative colitis.	Improving	enrollment delays or failure to advance Phase 2 study within 12 months	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-0.28

$-0.28 → $-0.28 · observed estimates

FY2027 revenue$0.05B

$0.05B → $0.05B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-0.28	$47,712,000	6 / 7
2026-07-25	$-0.28	$47,712,000	6 / 7
2026-07-26	$-0.28	$47,712,000	6 / 7
2026-07-27	$-0.29	$0	7 / 7
2026-07-28	$-0.29	$0	7 / 7
2026-07-29	$-0.28	$47,712,000	7 / 7
2026-07-30	$-0.29	$0	7 / 7
2026-07-31	$-0.28	$47,712,000	7 / 7
2026-08-01	$-0.28	$47,712,000	7 / 7
2026-08-02	$-0.29	$0	7 / 7
2026-08-03	$-0.28	$47,712,000	7 / 7
2026-08-04	$-0.28	$47,712,000	7 / 7
2026-08-05	$-0.29	$0	7 / 7
2026-08-06	$-0.29	$0	7 / 7
2026-08-07	$-0.28	$47,712,000	7 / 7
2026-08-08	$-0.29	$0	7 / 7
2026-08-09	$-0.29	$0	7 / 7
2026-08-10	$-0.29	$0	7 / 7
2026-08-12	$-0.27	$0	7 / 6
2026-08-13	$-0.27	$0	7 / 6
2026-08-14	$-0.28	$47,712,000	7 / 7
2026-08-15	$-0.28	$47,712,000	7 / 7
2026-08-16	$-0.28	$47,712,000	7 / 7
2026-08-17	$-0.28	$47,712,000	7 / 7
2026-08-18	$-0.28	$47,712,000	7 / 7
2026-08-19	$-0.28	$47,712,000	7 / 7
2026-08-20	$-0.28	$47,712,000	7 / 7
2026-08-21	$-0.28	$47,712,000	7 / 7
2026-08-22	$-0.28	$47,712,000	7 / 7
2026-08-23	$-0.28	$47,712,000	7 / 7
2026-08-24	$-0.28	$47,712,000	7 / 7
2026-08-25	$-0.28	$47,712,000	7 / 7
2026-08-26	$-0.28	$47,712,000	7 / 7
2026-08-27	$-0.28	$47,712,000	7 / 7
2026-08-28	$-0.28	$47,712,000	7 / 7
2026-08-29	$-0.28	$47,712,000	7 / 7
2026-08-30	$-0.28	$47,712,000	7 / 7
2026-08-31	$-0.28	$47,712,000	7 / 7
2026-09-01	$-0.28	$47,712,000	7 / 7
2026-09-02	$-0.28	$47,712,000	7 / 7
2026-09-03	$-0.28	$47,712,000	7 / 7
2026-09-04	$-0.28	$47,712,000	7 / 7
2026-09-05	$-0.28	$47,712,000	7 / 7
2026-09-06	$-0.28	$47,712,000	7 / 7
2026-09-07	$-0.28	$47,712,000	7 / 7
2026-09-08	$-0.28	$47,712,000	7 / 7
2026-09-09	$-0.28	$47,712,000	7 / 7
2026-09-10	$-0.28	$47,712,000	7 / 7
2026-09-11	$-0.28	$47,712,000	7 / 7
2026-09-12	$-0.28	$47,712,000	7 / 7
2026-09-13	$-0.28	$47,712,000	7 / 7
2026-09-14	$-0.28	$47,712,000	7 / 7
2026-09-15	$-0.28	$47,712,000	7 / 7
2026-09-16	$-0.28	$47,712,000	7 / 7
2026-09-17	$-0.28	$47,712,000	7 / 7
2026-09-18	$-0.28	$47,712,000	7 / 7
2026-09-19	$-0.28	$47,712,000	7 / 7
2026-09-20	$-0.28	$47,712,000	7 / 7
2026-09-21	$-0.28	$47,712,000	7 / 7
2026-09-22	$-0.28	$47,712,000	7 / 7
2026-09-23	$-0.28	$47,712,000	7 / 7
2026-09-24	$-0.28	$47,712,000	7 / 7
2026-09-25	$-0.28	$47,712,000	7 / 7
2026-09-26	$-0.28	$47,712,000	7 / 7
2026-09-27	$-0.28	$47,712,000	7 / 7
2026-09-28	$-0.28	$47,712,000	7 / 7
2026-09-29	$-0.28	$47,712,000	7 / 7
2026-09-30	$-0.28	$47,712,000	7 / 7
2026-10-01	$-0.28	$47,712,000	7 / 7
2026-10-02	$-0.28	$47,712,000	7 / 7
2026-10-03	$-0.28	$47,712,000	7 / 7
2026-10-04	$-0.28	$47,712,000	7 / 7
2026-10-05	$-0.28	$47,712,000	7 / 7
2026-10-06	$-0.28	$47,712,000	7 / 7
2026-10-07	$-0.28	$47,712,000	7 / 7
2026-10-08	$-0.28	$47,712,000	7 / 7
2026-10-09	$-0.28	$47,712,000	7 / 7
2026-10-10	$-0.28	$47,712,000	8 / 8
2026-10-11	$-0.28	$47,712,000	8 / 8
2026-10-12	$-0.28	$47,712,000	8 / 8
2026-10-13	$-0.28	$47,712,000	8 / 8
2026-10-14	$-0.28	$47,712,000	8 / 8
2026-10-15	$-0.28	$47,712,000	8 / 8
2026-10-16	$-0.28	$47,712,000	8 / 8
2026-10-17	$-0.28	$47,712,000	8 / 8
2026-10-18	$-0.28	$47,712,000	8 / 8
2026-10-19	$-0.28	$47,712,000	8 / 8
2026-10-20	$-0.28	$47,712,000	8 / 8
2026-10-21	$-0.28	$47,712,000	8 / 8
2026-10-22	$-0.28	$47,712,000	8 / 8
2026-10-23	$-0.28	$47,712,000	8 / 8
2026-10-24	$-0.28	$47,712,000	8 / 8

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	7	0	0
2026-06-01	8	0	0
2026-07-01	9	0	0
2026-08-01	9	0	0
2026-09-01	9	0	0
2026-10-01	10	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 10 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Strengthen Board and governance with new director appointmentsDirect metric needs a verified mapping
Maintain disciplined operating expense managementOperating income: $-11.698M
Advance Phase 2 study enrollment for PALI-2108 in Ulcerative ColitisDirect metric needs a verified mapping

Next proof point

Nov 9, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

3.1%Typical daily move · historical

Downside history

-52.5%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

PALISADE BIO INC outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is speculative clinical-stage growth, not an established earnings compounder. The long-term thesis is in a watch state: management is progressing PALI-2108, but recent financial performance is weak and the business is loss-making.

What's priced into PALISADE BIO INC

The valuation model indicates PALI is expensive versus peers, with low confidence in that estimate. The premium appears tied to the potential value of its development programs, while the evidence does not suggest the broader combination of expensive valuation, weak fundamentals, and turbulence is fully reflected in the fragility assessment.

What the fundamentals likely do

Near term, results may remain uneven: recent earnings were in line, but financial performance is weak relative to the industry and the next-print miss risk is flagged for monitoring. Over the multi-year view, management has advanced PALI-2108 into Phase 2 and says current cash can fund operations through key clinical milestones, though cash declined modestly from the first to the second quarter of 2026.

What PALISADE BIO INC hinges on

The central swing factor is whether the planned Phase 2 ASCENTRA-UC trial starts in the second half of 2026 and progresses toward the anticipated 2027 efficacy readout. The thesis also depends on cash remaining sufficient for those milestones; a guidance cut would be a negative signal, while stronger results and guidance from healthcare bellwethers could support sector momentum.